Xenon Pharmaceuticals Inc.

NASDAQ•XENE

CEO: Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-11-05

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Contact Information

3650 Gilmore Way, Suite 200, Burnaby, BC, V5G 4W8, Canada

604-484-3300

www.xenon-pharma.com

Market Cap

$4.40B

P/E (TTM)

-12.7

22.3

Dividend Yield

52W High

$63.95

52W Low

$28.19

52W Range

77%

Rank55Top 80.0%

2.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$1.17+0.00%

4-Quarter Trend

FCF

-$89.03M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Azetukalner Phase 3 Progress X-TOLE2 FOS topline data readout anticipated first half March 2026, supporting US regulatory submission plans.

Collaboration Revenue Secured Recognized $7.5M revenue from Neurocrine milestone payment in 2025, supporting operations and R&D.

Liquidity Position Maintained Ended 2025 with $199.2M cash and marketable securities available for operations and ongoing clinical funding.

R&D Investment Scale R&D expenses increased $90.5M to $300.9M in 2025, funding critical late-stage azetukalner development.

Risk Factors

Sustained Operating Losses Incurred $345.9M net loss in 2025; anticipates continued significant losses for foreseeable future indefinitely.

Clinical Success Uncertainty Azetukalner Phase 3 trials may fail to demonstrate adequate efficacy or safety, severely harming commercial prospects.

Future Capital Requirements Expect significant expenses requiring substantial additional capital raises, potentially causing shareholder dilution if financing is unavailable.

Regulatory Hurdles Remain Regulatory approval processes are lengthy and unpredictable, risking delays or denial for key indications like MDD and BPD.

Outlook

Epilepsy Data Timeline Expect topline data readout for Phase 3 X-TOLE2 FOS trial in first half March 2026 to support regulatory filings.

Neuropsychiatric Pipeline Advancement Phase 3 MDD (X-NOVA2) data expected H1 2027; BPD (X-CEED) study currently enrolling patients for evaluation.

Early-Stage Pipeline Progress Pain candidates XEN1120 and XEN1701 Phase 1 completion expected in 2026 to support subsequent Phase 2 initiation.

Commercial Preparation Focus Increasing G&A expenses reflect necessary investment in infrastructure for potential azetukalner commercial launch activities.

Peer Comparison

Revenue (TTM)

APLS

$1.11B

+42.5%

LEGN

$1.03B

+64.2%

RARE

$669.43M

+13.3%

Gross Margin (Latest Quarter)

TVTX

79.0%

+1.6pp

RARE

77.9%

-2.4pp

ZLAB

61.5%

-4.3pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CNTA	$6.13B	-24.3	-60.4%	1.1%
CELC	$6.07B	-37.3	-203.2%	41.9%
IMVT	$5.91B	-11.4	-65.8%	0.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Aug 10, 2026

EPS:-$1.15

Revenue:$1.50M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data